| Metric | Q3 2026 | Q3 2025 |
|---|---|---|
| Profit before tax | -18.9 | -30.6 |
| Net income | -18.9 | -30.6 |
| EPS (diluted, $ a share) | $-0.34 | $-2.19 |
A dash means the filing did not report that period. Growth is not shown when either period was a loss. Figures from the filing's XBRL data.
10-Q filed with the SEC, NASDAQ: AVTX. Figures from the filing's XBRL data; summary written with AI assistance from the filing.
Avalo Therapeutics, Inc.: key numbers
- Share price
- $7.13Close, Nov 17
- Market cap
- $412M
- Shares outstanding
- 57.82MLatest SEC cover page
- Sector
- Life Sciences
- Industry
- Pharmaceutical PreparationsSIC 2834
Today's reference numbers, updated daily. Not a valuation or a recommendation.
More from Avalo Therapeutics, Inc.
All →Avalo Therapeutics Capital Raise
Avalo Therapeutics entered into an at-the-market (ATM) sales agreement with Jefferies LLC to establish a program for the potential issuance and sale of up to $200 million of common stock. Simultaneously, the company terminated its existing sales agreement with TD Securities (USA) LLC (formerly TD Cowen) that had been in place since June 2025.
- Counterparty
- Jefferies LLC
Avalo Therapeutics Financial Results
Avalo Therapeutics reported its third quarter 2026 financial results, highlighting a cash position of $462.8 million which is expected to fund operations into 2029. The company is advancing its lead candidate, abdakibart, toward a Phase 3 program in hidradenitis suppurativa with initiation planned for the first half of 2027.
“LOTUS provides a strong clinical foundation for advancing abdakibart toward registrational development in hidradenitis suppurativa. The efficacy and safety results observed across both dosing regimens, together with the potential for once-monthly administration, give us confidence in abdakibart’s potential to become an important new treatment option for patients with HS.”
Garry Neil, MD, Chief Executive Officer
Avalo Therapeutics CFO Christopher Ryan Sullivan Sells $202K of Stock
Christopher Ryan Sullivan, CFO, sold 12,394 shares of Avalo Therapeutics, Inc. at $16.33 a share, worth $202K in total on Sep 16, 2026. Shares held after the trade: 39,900 (-23.7%).
- Value
- $202K
- Shares
- 12,394
- Price
- $16.33
- Role
- CFO
- Holding change
- -23.7%
- Trade date
- Sep 16, 2026